Rheumatoid arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application form (PB324)

Use this form to apply for change of treatment from PBS-subsidised biological medicine to tocilizumab after resolution of critical shortage of tocilizumab for patients with rheumatoid arthritis.

'Biological agent' refers to:

  • abatacept
  • adalimumab
  • baricitinib
  • certolizumab pegol
  • etanercept
  • golimumab
  • infliximab
  • rituximab
  • tofacitinib
  • upadacitinib.

Download and complete the Rheumatoid arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application form.

Page last updated: 17 November 2022.
QC 55885